Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
OMEGA THERAPEUTICS INC (OMGA) Stock Price & Overview
NASDAQ:OMGA • US68217N1054
Current stock price
0.1426 USD
-0.02 (-10.82%)
At close:
0.11 USD
-0.03 (-22.86%)
After Hours:
The current stock price of OMGA is 0.1426 USD. Today OMGA is down by -10.82%. In the past month the price decreased by -71.98%. In the past year, price decreased by -96.68%.
OMGA Key Statistics
52-Week Range0.0953 - 4.4396
Current OMGA stock price positioned within its 52-week range.
1-Month Range0.0953 - 0.67
Current OMGA stock price positioned within its 1-month range.
- Market Cap
- 7.896M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.33
- Dividend Yield
- N/A
OMGA Stock Performance
Today
-10.82%
1 Week
-37.95%
1 Month
-71.98%
3 Months
-83.85%
Longer-term
6 Months -90.30%
1 Year -96.68%
2 Years -97.79%
3 Years -98.80%
5 Years N/A
10 Years N/A
OMGA Stock Chart
OMGA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to OMGA. When comparing the yearly performance of all stocks, OMGA is a bad performer in the overall market: 99.58% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
OMGA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OMGA. OMGA may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
OMGA Earnings
On March 6, 2025 OMGA reported an EPS of -0.3 and a revenue of 2.61M. The company missed EPS expectations (-6.31% surprise) and beat revenue expectations (106.48% surprise).
Next Earnings DateN/A
Last Earnings DateMar 6, 2025
PeriodQ3 / 2024
EPS Reported-$0.30
Revenue Reported2.612M
EPS Surprise -6.31%
Revenue Surprise 106.48%
OMGA Forecast & Estimates
7 analysts have analysed OMGA and the average price target is 13.26 USD. This implies a price increase of 9198.74% is expected in the next year compared to the current price of 0.1426.
For the next year, analysts expect an EPS growth of 34.35% and a revenue growth 233.18% for OMGA
Analysts
Analysts82.86
Price Target13.26 (9198.74%)
EPS Next Y34.35%
Revenue Next Year233.18%
OMGA Financial Highlights
Over the last trailing twelve months OMGA reported a non-GAAP Earnings per Share(EPS) of -1.33. The EPS increased by 36.06% compared to the year before.
Income Statements
Revenue(TTM)8.10M
Net Income(TTM)-73.09M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.86% | ||
| ROE | -633.21% | ||
| Debt/Equity | 1 |
Chartmill High Growth Momentum
EPS Q2Q%25%
Sales Q2Q%214.32%
EPS 1Y (TTM)36.06%
Revenue 1Y (TTM)184.04%
OMGA Ownership
Ownership
Inst Owners81.36%
Shares55.37M
Float50.93M
Ins Owners1.4%
Short Float %N/A
Short RatioN/A
OMGA Industry Overview
OMGA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
66%
Outperformed 66% of sub-industries
3 Month Rank
48%
Outperformed 48% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.8%
- New Lows
- 3.1%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.2
- Average Fwd P/E
- 22.5
- Average Debt/Equity
- 2.1
OMGA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.65 | 349.666B | ||
| AMGN | AMGEN INC | 14.7 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.56 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.72 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.64 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.47 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 11.82 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.61 | 24.944B | ||
| INCY | INCYTE CORP | 10.76 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OMGA
Company Profile
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-07-30. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The firm designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
Company Info
IPO: 2021-07-30
OMEGA THERAPEUTICS INC
140 First Street, Suite 501
Cambridge MASSACHUSETTS US
CEO: Mahesh Karande
Employees: 94
Phone: 16179494360
OMEGA THERAPEUTICS INC / OMGA FAQ
What does OMEGA THERAPEUTICS INC do?
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-07-30. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The firm designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
What is the current price of OMGA stock?
The current stock price of OMGA is 0.1426 USD. The price decreased by -10.82% in the last trading session.
Does OMEGA THERAPEUTICS INC pay dividends?
OMGA does not pay a dividend.
What is the ChartMill rating of OMEGA THERAPEUTICS INC stock?
OMGA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is OMGA stock listed?
OMGA stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of OMGA stock?
OMEGA THERAPEUTICS INC (OMGA) operates in the Health Care sector and the Biotechnology industry.